Literature DB >> 19729045

Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles.

Brian R Sloat1, Michael A Sandoval, Andrew M Hau, Yongqun He, Zhengrong Cui.   

Abstract

An accumulation of research over the years has demonstrated the utility of nanoparticles as antigen carriers with adjuvant activity. Herein we defined the adjuvanticity of a novel lecithin-based nanoparticle engineered from emulsions. The nanoparticles were spheres of around 200nm. Model protein antigens, bovine serum albumin (BSA) or Bacillus anthracis protective antigen (PA) protein, were covalently conjugated onto the nanoparticles. Mice immunized with the BSA-conjugated nanoparticles developed strong anti-BSA antibody responses comparable to that induced by BSA adjuvanted with incomplete Freund's adjuvant and 6.5-fold stronger than that induced by BSA adsorbed onto aluminum hydroxide. Immunization of mice with the PA-conjugated nanoparticles elicited a quick, strong, and durable anti-PA antibody response that afforded protection of the mice against a lethal dose of anthrax lethal toxin challenge. The potent adjuvanticity of the nanoparticles was likely due to their ability to move the antigens into local draining lymph nodes, to enhance the uptake of the antigens by antigen-presenting cells (APCs), and to activate APCs. This novel nanoparticle system has the potential to serve as a universal protein-based vaccine carrier capable of inducing strong immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729045      PMCID: PMC2789915          DOI: 10.1016/j.jconrel.2009.08.023

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  29 in total

1.  Adjuvant activity of incomplete Freund's adjuvant.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-07-06       Impact factor: 15.470

Review 2.  Microparticles and nanoparticles as delivery systems for DNA vaccines.

Authors:  Zhengrong Cui; Russell J Mumper
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2003       Impact factor: 4.889

3.  Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Authors:  Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

4.  Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.

Authors:  Zhengrong Cui; Paul R Lockman; Craig S Atwood; Cheng-Hsuan Hsu; Anshul Gupte; David D Allen; Russell J Mumper
Journal:  Eur J Pharm Biopharm       Date:  2005-02       Impact factor: 5.571

Review 5.  Nanoparticles and microparticles as vaccine-delivery systems.

Authors:  Manmohan Singh; Aravind Chakrapani; Derek O'Hagan
Journal:  Expert Rev Vaccines       Date:  2007-10       Impact factor: 5.217

6.  Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.

Authors:  Z Shen; G Reznikoff; G Dranoff; K L Rock
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

7.  Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli.

Authors:  Brian R Sloat; Zhengrong Cui
Journal:  Vaccine       Date:  2006-06-19       Impact factor: 3.641

8.  Stable biocompatible adjuvants--a new type of adjuvant based on solid lipid nanoparticles: a study on cytotoxicity, compatibility and efficacy in chicken.

Authors:  Carsten Olbrich; Rainer Helmut Müller; Kerstin Tabatt; Oliver Kayser; Christoph Schulze; Rüdiger Schade
Journal:  Altern Lab Anim       Date:  2002 Jul-Aug       Impact factor: 1.303

Review 9.  Aluminum salts in vaccines--US perspective.

Authors:  Norman W Baylor; William Egan; Paul Richman
Journal:  Vaccine       Date:  2002-05-31       Impact factor: 3.641

10.  Induction of protective immunity against lethal anthrax challenge with a patch.

Authors:  Richard T Kenney; Jianmei Yu; Mimi Guebre-Xabier; Sarah A Frech; Adam Lambert; Barbara A Heller; Larry R Ellingsworth; James E Eyles; E Diane Williamson; Gregory M Glenn
Journal:  J Infect Dis       Date:  2004-07-13       Impact factor: 5.226

View more
  34 in total

1.  Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design.

Authors:  Xinran Li; Brian R Sloat; Nijaporn Yanasarn; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2010-12-21       Impact factor: 5.571

2.  Lipid nanocapsule as vaccine carriers for his-tagged proteins: evaluation of antigen-specific immune responses to HIV I His-Gag p41 and systemic inflammatory responses.

Authors:  Saurabh Wadhwa; Anekant Jain; Jerold G Woodward; Russell J Mumper
Journal:  Eur J Pharm Biopharm       Date:  2011-10-31       Impact factor: 5.571

3.  In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.

Authors:  Brian R Sloat; Michael A Sandoval; Dong Li; Woon-Gye Chung; Dharmika S P Lansakara-P; Philip J Proteau; Kaoru Kiguchi; John DiGiovanni; Zhengrong Cui
Journal:  Int J Pharm       Date:  2011-03-01       Impact factor: 5.875

Review 4.  Applications of nanomaterials as vaccine adjuvants.

Authors:  Motao Zhu; Rongfu Wang; Guangjun Nie
Journal:  Hum Vaccin Immunother       Date:  2014-11-17       Impact factor: 3.452

Review 5.  Unintended effects of drug carriers: Big issues of small particles.

Authors:  Hamideh Parhiz; Makan Khoshnejad; Jacob W Myerson; Elizabeth Hood; Priyal N Patel; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

6.  Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.

Authors:  Dharmika S P Lansakara-P; B Leticia Rodriguez; Zhengrong Cui
Journal:  Int J Pharm       Date:  2012-03-16       Impact factor: 5.875

7.  Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens.

Authors:  Nijaporn Yanasarn; Brian R Sloat; Zhengrong Cui
Journal:  Mol Pharm       Date:  2011-06-07       Impact factor: 4.939

8.  Aluminum (Oxy)Hydroxide Nanosticks Synthesized in Bicontinuous Reverse Microemulsion Have Potent Vaccine Adjuvant Activity.

Authors:  Xu Li; Stephanie Hufnagel; Haiyue Xu; Solange A Valdes; Sachin G Thakkar; Zhengrong Cui; Hugo Celio
Journal:  ACS Appl Mater Interfaces       Date:  2017-06-29       Impact factor: 9.229

9.  Tresyl-based conjugation of protein antigen to lipid nanoparticles increases antigen immunogenicity.

Authors:  Anekant Jain; Weili Yan; Keith R Miller; Ronan O'Carra; Jerold G Woodward; Russell J Mumper
Journal:  Int J Pharm       Date:  2010-09-15       Impact factor: 5.875

10.  A solid lipid nanoparticle formulation of 4-(N)-docosahexaenoyl 2', 2'-difluorodeoxycytidine with increased solubility, stability, and antitumor activity.

Authors:  Solange A Valdes; Riyad F Alzhrani; Andres Rodriguez; Dharmika S P Lansakara-P; Sachin G Thakkar; Zhengrong Cui
Journal:  Int J Pharm       Date:  2019-08-12       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.